Anderson et al. Serial No.: 09/585,475 Page 9 of 9

REMARKS/ARGUMENTS

In response to the Final Rejection mailed January 30, 2004, Applicants have amended claims 93-94, added new claims 98-105 and present the following remarks. Claims 85-94, 96 and 97-105 are pending. Claims 1-84, and 95 have been canceled.

Claim 93 and 94 were objected to as containing a typographical error "claim10" and "antipipemic". These typos have been corrected. Accordingly, this objection should be withdrawn.

New claims 98-105 were added which are specifically directed to markers for antilipemic agents. Not only are the protein markers listed not previously known as toxicity or efficacy markers, but nothing in the prior art suggests that these proteins are even likely to be considered markers for treatment with suspected or actual antilipemic agents.

In view of the above amendments and previous comments, the claims are now in conditions for allowance and applicants request a timely Notice of Allowance be issued in this application.

The commissioner hereby is authorized to charge payment of any fees under 37 CFR § 1.17, which may become due in connection with the instant application or credit any overpayment to Deposit Account No.500933.

Respectfully submitted,

lm E. Tenza

John E. Tarcza

Date: July 27, 2004 Reg. No. 33,638

John E. Tarcza
Intellectual Property Advisor
Large Scale Biology Corporation
3333 Vaca Valley Parkway, Suite 1000
Vacaville, CA 95688
301-371-7740 tel.
301-371-7745 Fax.
E-MAIL john.tarcza@lsbc.com